Hepatology
From the Journals
Novel microbiome signature may detect NAFLD-cirrhosis
The microbial biomarker showed strong diagnostic accuracy for identifying cirrhosis in patients with NAFLD.
From the Journals
For patients with HBV, daily aspirin may reduce risk of liver cancer
Sixteen years of data showed that daily aspirin therapy reduced the risk of HBV-related hepatocellular carcinoma by 29%.
From the Journals
For patients with end-stage liver disease, acute care incurs steep costs
Mean end-of-life costs exceeded those for ischemic heart disease, diabetes, mental health disorders, and congestive heart failure. Only chronic...
Video
DDNA19: The NASH conundrum
The optimal treatment of NASH.
From the Journals
Cirrhosis model predicts decompensation across diverse populations
During model development, the hazard ratio for decompensation was 7.10 among patients with high risk scores.
Conference Coverage
Will inpatient albumin help in decompensated cirrhosis?
PHILADELPHIA – Recent studies provide conflicting results, though a randomized, phase 3 trial in progress may...
Video
DDNA19: Cardiac Complications in Liver Disease Patients
Dr. Marc Klapholz explains the latest developments in portopulmonary arterial hypertension, hepatopulmonary syndrome, and cirrhotic...
From the Journals
One-time, universal hepatitis C testing cost effective, researchers say
Compared with birth cohort screening alone, universal one-time screening for hepatitis C was cost effective as long as the prevalence of chronic...
From the Journals
Women survive more often than men do when hospitalized with cirrhosis
Women more often had infections and comorbidities, while men more often had liver decompensation, which contributed most significantly to their...
From the Journals
Developing an HCV vaccine faces significant challenges
From the Journals
Possible biomarkers found for progression to liver cancer in chronic HCV infection
Mannose-binding lectin and ficolin-2 are potential biomarkers for the development of liver cancer in chronic HCV infection.